We have received the following from CredibleMeds. Subscribe to their newsletter if you would like to receive regular updates from them too.
June 26, 2023
Re: Changes to the QTdrugs List and List of Drugs to Avoid in cLQTS
Dear CredibleMeds Registrants:
AZCERT’s Scientific Review Committee has found substantial evidence that Pacritinib (anticancer), Vernakalant (antiarrhythmic) and Fexinidazole (antiparasitic) are associated with the development of QT prolongation but lack convincing evidence of torsades de pointes (TdP). Therefore, these drugs have been added to the Possible Risk of TdP category (PR) and the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (DTA List).
As demonstrated by these revisions, the QTdrugs list is dynamic and changes regularly. To perform a quick search of the Lists we recommend using the CredibleMeds website and the smartphone app (Apple or Android).
Ray Woosley and the Scientific Review Committee for AZCERT
Will Heise, MD
Klaus Romero, MD
Tyler Gallo, PharmD
R. David Woosley, MPH
Joseph Lambson, PharmD